Researchers recently enhanced the titer of a cell line still in development to produce adenovirus viral vectors by 7.5-fold, and without the risk of also producing replication-competent adenoviruses ...
Phase I and Pharmacokinetic Study of the Ribonucleotide Reductase Inhibitor, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, Administered by 96-Hour Intravenous Continuous Infusion Virus-directed ...
As gene and cell therapies mature, developers are increasingly looking beyond existing delivery systems to address challenges around targeting, immunogenicity, manufacturability, and cost. Dr. Angelo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results